Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
ATNM shares plummeted 64% to $2.20 after FDA ruling. FDA found ATNM's Phase 3 trial insufficient for a Biologics License Application. The market is reacting negatively to regulatory setbacks affecting ATNM's future.
- ATNM shares plummeted 64% to $2.20 after FDA ruling.
- FDA found ATNM's Phase 3 trial insufficient for a Biologics License Application.
- The market is reacting negatively to regulatory setbacks affecting ATNM's future.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.